Enhancement of anticancer agent activity by selective inhibition of rapidly proliferating tissues of the host.
Most cytotoxic drugs used in cancer therapy do not discriminate between neoplastic and normal proliferating cells. To avoid irreversible damage to vital host tissues, such as bone marrow and intestine, drugs must be administered at dosages which usually prove insufficient to eradicate all of the neoplastic cells present. This review focuses on an approach to improve cancer chemotherapy by selectively protecting normal, proliferating cells during treatment, thereby permitting the administration of otherwise lethal doses of drug. Preclinical in vivo studies of cytokinetic modulation with interferon, or L-histidinol, as well as recent clinical studies of interferon modulation of the activity of 5-fluorouracil are reviewed.
Stolfi
R L
RL
Catholic Medical Center of Brooklyn & Queens, Woodhaven, NY 11421.
Martin
D S
DS
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects*; D004357:Drug Synergism; D006641:Histidinol / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D006641:Histidinol; D007372:Interferons